SuperworthIovance Biotherapeutics price to sales ratio IOVA
Market value divided by revenue over the last twelve months, since 2024.
- Today, Oct 23, 2026
- 19.6×
- 2-year median
- 6.4×
- Against its 2-year history
- 76th
- percentile: 0 is its lowest day, 100 its highest
- 2-year range
- 2.6× to 110×
- Peer median
- 7.5×
Iovance Biotherapeutics' price to sales ratio is 19.6× as of Oct 23, 2026.
That is above its 2-year median of 6.4×, higher than on 76% of days in the last 2 years.
Over that time it ranged from 2.6× in May 2025 to 110× in Aug 2024.
The median for 10 biotech stocks of a similar size is 7.5×.
Price to sales ratio over time
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2026 so far | 19.6× | 3.7× | 20.4× |
| 2025 | 4.5× | 2.6× | 25.7× |
| 2024 | 24.7× | 24.7× | 110× |
Against its peers
Companies in Biotechnology nearest Iovance Biotherapeutics' size, closest first, today.
| Company | Price to sales ratio |
|---|---|
| IOVAIovance Biotherapeutics | 19.6× |
| KRYSKrystal Biotech | 20.9× |
| RGENRepligen | 12.7× |
| TECHBIO-TECHNE | 9.4× |
| HALOHalozyme Therapeutics | 8.6× |
| NBIXNeurocrine Biosciences | 4.3× |
| EXELExelixis | 6.6× |
| ADMAAdma Biologics | 4.7× |
| VCELVericel | 7.1× |
| INCYIncyte | 4.0× |
| UTHRUnited Therapeutics | 8.0× |
| Peer median | 7.5× |
Where Iovance Biotherapeutics ranks
What the price to sales ratio tells you
Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.
Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.
More on Iovance Biotherapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.